Company news: Novo Nordisk

Share this article:
Novo Nordisk launched a hemophilia app, dubbed HemaGo, which lets patients and caregivers track treatment, dosing and bleed information while monitoring the disease's impact on life events.  Patients enter information, which is then sent to Novo Nordisk's ‘Changing Possibilities in Hemophilia' website and assembled into easy-to-read reports which to be shared with healthcare providers. HemaGo will be available on both Android and Apple platforms.

An aging and increasingly-affluent population, together with forthcoming Rx-to-OTC switches, stands to boost the $32 billion Chinese OTC market, said consultancy Kline & Co., which said growth in the category is six times stronger than in the US, and noting that China's answer to the FDA is weighing broadening its list of indications that OTC drugs may carry to include chronic conditions like high cholesterol, asthma, osteoporosis, migraine and peptic ulcers.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.

Insurers get personal to nip costs

Healthcare insurers seek to curb diabetes costs with interventions that may include house calls.

Novartis dials down RNA research

The drugmaker says the therapeutic approach has a narrow treatment potential.